BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small ...

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has ...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) used a presentation at Leerink Partners’ Global Healthcare Conference to outline its strategy around “next-generation RAS therapeutics,” highlighting thre ...

DoorDash announced Tuesday its intention to acquire startup ordering and payment solutions platform, Bbot. The deal is expected to be finalized by the end of this quarter and will introduce tableside ...

Just weeks after DoorDash reported a stellar Q4, the company has announced it will buy Bbot, a startup that makes order-and-pay software for restaurants and other hospitality venues. The acquisition ...

BBO-8520 monotherapy in patients with KRAS G12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients ...

Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple KRAS G12D and KRAS G12V cell-derived xenograft (CDX) ...

As bars and restaurants across the globe contemplate how to safely serve diners during the pandemic, many establishments are seeking ways to reduce the number of touchpoints between servers and guests ...

NEW YORK, July 22, 2021 /PRNewswire/ — Bbot, a hospitality tech startup dedicated to simplifying and improving the ordering and payments process for restaurants, today announces $15 million in Series ...